Nusinersen for Spinal Muscular Atrophy: Are We Paying Too Much for Too Little?
- PMID: 29228077
- DOI: 10.1001/jamapediatrics.2017.4360
Nusinersen for Spinal Muscular Atrophy: Are We Paying Too Much for Too Little?
Erratum in
-
Missing Potential Conflict of Interest.JAMA Pediatr. 2018 Sep 1;172(9):891. doi: 10.1001/jamapediatrics.2018.2493. JAMA Pediatr. 2018. PMID: 30073265 No abstract available.
Comment in
-
Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy-Reply.JAMA Pediatr. 2018 Jul 1;172(7):701-702. doi: 10.1001/jamapediatrics.2018.0733. JAMA Pediatr. 2018. PMID: 29800980 No abstract available.
-
Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy.JAMA Pediatr. 2018 Jul 1;172(7):701. doi: 10.1001/jamapediatrics.2018.0772. JAMA Pediatr. 2018. PMID: 29801053 No abstract available.
-
Inconsistent Reporting of Potential Conflicts of Interest.JAMA Pediatr. 2018 Sep 1;172(9):886. doi: 10.1001/jamapediatrics.2018.2420. JAMA Pediatr. 2018. PMID: 30073291 No abstract available.
Comment on
-
Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy.JAMA Pediatr. 2018 Feb 1;172(2):188-192. doi: 10.1001/jamapediatrics.2017.4409. JAMA Pediatr. 2018. PMID: 29228163
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical